Abstract: The present invention relates to compounds of formula I wherein R, R4 and Q are each as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 pathway (HSF1 pathway). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.

Abstract: The present invention relates to compounds of formula I wherein R, R4 and Q are each as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 pathway (HSF1 pathway). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.

Abstract: Medical treatment simulation systems and devices are disclosed. One device includes an overlay, a simulated treatment structure, at least one feedback device, and at least one processor. The overlay is configured to be secured to the live subject and to cover at least a portion of a body of the live subject. The simulated treatment structure is configured to simulate a structure associated with the medical procedure. The at least one feedback device is configured to provide a feedback signal to the live subject. The at least one processor is connected to the simulated treatment structure and the at least one feedback device. The processor is programmed to operate the feedback device to provide the feedback signal based upon input generated from interaction between a treatment provider and the simulated treatment structure. The disclosed devices may be used to simulate intravenous, catheter, defibrillation, and/or thoracic treatments.